AstraZeneca spinout Viela bags $75M as FDA filing nears

fiercebiotech | June 18, 2019

AstraZeneca spinout Viela Bio has raised $75 million to take anti-CD19 antibody inebilizumab toward approval. The series B round comes 16 months after Viela broke free from AstraZeneca with six drugs and $250 million in funding. Since then, a late-phase trial of inebilizumab in patients with neuromyelitis optica spectrum disorder (NMOSD) has hit its primary endpoint, teeing Viela up to file for FDA approval later in the year. To fund the filing and pre-commercial work, Viela has brought additional investors on board. HBM Healthcare Investments led the series B with the support of new investors including Viking Global Investors, Cormorant Asset Management, Terra Magnum Capital Partners, Goldman Sachs and Barer & Son Capital. Temasek was among the existing investors to contribute to the series B. The willingness of the investors to add to Viela’s coffers reflects the potential of inebilizumab. In the late-phase trial, patients with the rare autoimmune disease NMOSD experienced a 77% reduction in the risk of suffering an attack. NMOSD attacks can lead to blindness and paralysis. Viela’s top priority is to bring the drug to market in NMOSD, a condition for which there are no FDA-approved treatments. The Maryland-based biotech is also interested in developing inebilizumab in other indications—AstraZeneca trialed the antibody in multiple sclerosis, systemic scleroderma and B-cell malignancies—and in advancing the other assets it picked up from its parent company.

Spotlight

Hot Melt Extrusion (HME) is an enabling processing technology that dates back many decades in the plastics, food, and other industries, and has been applied in pharmaceuticals for nearly 30 years now. Pharmaceutical manufacturers choose HME to enable poorly soluble compounds. When executed properly, HME advances poorly soluble compounds in the development pipeline, without adding delays, cost, or significant post-processing activities, and can scale to commercial manufacturing.

Spotlight

Hot Melt Extrusion (HME) is an enabling processing technology that dates back many decades in the plastics, food, and other industries, and has been applied in pharmaceuticals for nearly 30 years now. Pharmaceutical manufacturers choose HME to enable poorly soluble compounds. When executed properly, HME advances poorly soluble compounds in the development pipeline, without adding delays, cost, or significant post-processing activities, and can scale to commercial manufacturing.

Related News

Precision Virologics and Bharat Biotech Jointly Obtain Rights to Intranasal COVID-19 Vaccine Technology

Precision Virologics | September 23, 2020

Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a vaccine manufacturing giant, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets. The licensing agreements will lead to rapid clinical development, following the intranasal vaccine candidate having shown unprecedented levels of protection in mouse studies. This technology and data recently was published in Cell and Nature. "The ability to accomplish effective immunization with a single nasal dose is a major advantage, offering broader reach and easier administration," said Precision Virologics Interim CEO David T. Curiel, MD, PhD. "An effective nasal dose not only protects against COVID-19, but it also prevents the spread of the disease by directly targeting the cells that line the nose and throat. Most other vaccine candidates currently under development can't do that." Based on these exceptional findings, the National Institutes of Health is advancing studies in non-human primates. Phase I trials – a single nasal dose – will take place at Saint Louis University's Vaccine and Treatment Evaluation Unit. Bharat Biotech, upon obtaining regulatory approvals, will pursue clinical trials in India and undertake large-scale manufacture of the vaccine at its GMP facility in Genome Valley, India.

Read More

CELL AND GENE THERAPY

TaiGen Partners with GPCR to develop Burixafor & Taigexyn(R)

Burixafor | November 09, 2020

TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercialization of Taigexyn® (nemonoxacin) in South Korea. Burixafor is a highly potent CXCR4 inhibitor currently under clinical development. It can be used as a stem cell mobilizer for hematopoietic stem cell transplantation and a chemosensitizer in hematological and solid tumors. It can also be used for stem cell collection in healthy individuals for personalized regenerative medicine. Taigexyn® is a novel safe and effective antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria. Under the terms of the agreement, GPCR Therapeutics will be wholly responsible for the development, registration, and commercialization of Taigexyn® in S. Korea and Burixafor worldwide. Apart from upfront fees, TaiGen will receive shares of GPCR Therapeutics as well as future milestone and royalty payments.

Read More

Bio-K Plus International is expanding its portfolio of probiotic products and is launching a new line of functional beverages infused with probiotics

Bio-K | October 22, 2020

Bio-K Plus International Inc. (Bio-K Plus), pioneer in the probiotic sector and leader in the biotech industry, is pleased to announce the launch of its new line of functional beverages, Essential. Focused on offering premium quality probiotics that make a real difference in people's lives around the world, the company is adding the Essential line to its existing Pro and Original lines. In keeping with this tradition of high quality, the Essential line fits perfectly into the active and modern lifestyle of today's consumer, always looking for innovative ways to stay healthy. Bio-K Plus offers a dose of probiotics in the form of fun, delightful and balanced functional beverages. This announcement is the result of more than two years of research and development carried out by Bio-K Plus' experienced team that has developed the best line of functional beverages infused with probiotic bacteria. This project was led by Martin Croteau, Chief Commercial Officer, and was driven by the need to democratize probiotics, making them more accessible for all, and broaden their use to support global health in a more holistic manner.

Read More